Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck emend (aprepitant/fosaprepitant — CINV supportive care, legacy) — U.S. sales ($M) ($M)
Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b
Latest, Q4 2020
0
Period ended Dec 31, 2020
Change on a year earlier
-100.0%
10 in Q4 2019
History
16 quarters
Since Q1 2017
Sources
11
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Emend (aprepitant/fosaprepitant — CINV supportive care, legacy) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2020 | Dec 31, 2020 | 0 | -100.0% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2020 | Sep 30, 2020 | 8 | -81.0% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 6 | -91.0% | Form 10-Q (filed 2020-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 5 | -92.1% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 10 | -86.3% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 42 | -40.8% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 67 | -24.7% | Form 10-Q (filed 2020-08-05) ↗ |
| Q1 2019 | Mar 31, 2019 | 63 | -20.3% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2018 | Dec 31, 2018 | 73 | -14.1% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2018 | Sep 30, 2018 | 71 | -19.3% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2018 | Jun 30, 2018 | 89 | +7.2% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2018 | Mar 31, 2018 | 79 | -8.1% | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2017 | Dec 31, 2017 | 85 | – | Form 10-K (filed 2020-02-26) ↗ |
| Q3 2017 | Sep 30, 2017 | 88 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 83 | – | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 86 | – | Form 10-Q (filed 2018-05-08) ↗ |
Cite this data
StockData. (2026). Merck Emend (aprepitant/fosaprepitant — CINV supportive care, legacy) — U.S. sales ($M) ($M), quarterly Q1 2017–Q4 2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_emend_us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.